WM Artphoto, Maria Westling

We are a research-based company in the cancer diagnostic field. We are developing ColoNode® – a biomarker test for accurate detection and characterization, of cancer cells in lymph nodes of colorectal cancer patients.

Colorectal cancer is the third most common cancer worldwide. Half of all patients die from the disease, despite available treatments. Additional chemotherapy following surgery can reduce the risk of recurrent cancer, but the currently used methods for selecting patients for different treatment options are inaccurate and ineffective. This results in both over- and undertreatment with unnecessary human suffering and high costs.

HiloProbe is developing a highly accurate test to identify each patient’s need of treatment after surgery for colorectal cancer. Examination of lymph node tissue with ColoNode® offers clinicians a rapid, objective and accurate routine for detection of cancer cells and determination of their aggressiveness.

THOMAS BUSCH APPOINTED NEW CHAIRMAN OF THE BOARD AT HILOPROBE AB

Thomas Busch has taken over as Chairman of the Board at Swedish biotech company Hiloprobe AB at what he calls “an exciting time” for the thriving business. “We are now ready to transition from a research company to actively marketing and selling our ColoNode biomarker...

New promising ColoNode results

Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode's benefits and usefulness in colon cancer. “The results look...

HiloProbe enters strategically important partnership with Biocartis

We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries. For more information please read Biocartis...

HiloProbe participates at major surgeon congress in Dublin

HiloProbe has participated in a major international surgeon congress in Dublin. - Surgeons are one of our main stakeholders and therefore it important to meet, discuss and present data to them, says Lina Olsson, CEO. HiloProbe participated at the well-attended ESCP...

HiloProbe CE-marks ColoNode

HiloProbe has CE-marked the ColoNode to satisfy the needs of potential customers who want to start testing the product. - Research Use Only was not enough. Therefore, we have put a lot of focus and resources into completing CE documentation according to IVDD in order...

Funded by